Manisha H. Shah MD

Manisha H. Shah MD
ProfessorCollege of Medicineshah.171@osu.edu
A441 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-8629Fax: 614-293-4372
  • Experimental Therapeutics

General Research Interest

Clinical research in Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers.

Research Description

Our group focuses on discovering new targeted therapies for patients with Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers. We offer phase II-III clinical trials in these types of cancers. We lead many national studies. We conduct pre-clinical studies to learn types of drugs and combination of drugs and apply that knowledge to design clinical trials. We also perform several tests on tumor genetics, tumor imaging, pharmacokinetics and pharmacodynamics of study drugs as part of our clinical trials.

Transinstitutional Work

We collaborate with other centers to perform clinical trials in Neuroendocrine cancers, Thyroid cancers and Adrenal Cancers.

Current Publications

  • Haraldsdottir S, Shah MHAn update on clinical trials of targeted therapies in thyroid cancer.Curr Opin Oncol 26 36-44 1/1/2014
  • Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SICabozantinib in progressive medullary thyroid cancer.J Clin Oncol 31(29) 3639-46 10/10/2013
  • Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, Gregory G, Khabiri H, Shah M, Bloomston MExtrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma.Ann Surg Oncol 20(4) 1114-20 4/1/2013
  • Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PGComplete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Clin Cancer Res 18(11) 3170-9 6/1/2012
  • Jones NB, Shah MH, Bloomston MLiver-directed therapies in patients with advanced neuroendocrine tumors.J Natl Compr Canc Netw 10(6) 765-74 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu